Cite
HARVARD Citation
Mulligan, M. et al. (2014). Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open forum infectious diseases. p. . [Online].